SELLAS Life Sciences (SLS) Operating Income Growth (1y) (2013 - 2026)
SELLAS Life Sciences (SLS) Operating Income Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 1,386.07% |
| 10 | SELLAS Life Sciences | 1.90 Bn | 1.79 Bn | - | -52.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.60% |
| Dec 31, 2025 | -19.33% |
| Sep 30, 2025 | 3.36% |
| Jun 30, 2025 | 9.81% |
| Mar 31, 2025 | 37.14% |
| Dec 31, 2024 | 15.40% |
| Sep 30, 2024 | 21.71% |
| Jun 30, 2024 | 15.79% |
| Mar 31, 2024 | 14.50% |
| Dec 31, 2023 | 13.43% |
| Sep 30, 2023 | -31.00% |
| Jun 30, 2023 | -4.95% |
| Mar 31, 2023 | 32.59% |
| Dec 31, 2022 | 18.70% |
| Sep 30, 2022 | -2.42% |
| Jun 30, 2022 | -93.64% |
| Mar 31, 2022 | -645.43% |
| Dec 31, 2021 | -179.37% |
| Sep 30, 2021 | -55.32% |
| Jun 30, 2021 | -4.36% |